In-Vitro Cytotoxicity Testing
We currently have over 400 mammalian cells with 370 different human cancer cell lines, as well as numerous Primary human cells (e.g., HEKa, HUVEC, HMVEC, NHDF, NHEK, PBMC). We already perform hundreds of anticancer drug testing. We can analyze the biological activity of your compound by itself or in combination with known anticancer drug. See below for a full list of anti-cancer drugs currently available.

Please contact us with any request for cell-based Toxicity Testing. We can perform any Non Radioactive Cytotoxicity Assay (e.g. The MultiTox-Glo Multiplex Cytotoxicity Assay, ApoGlow). Moreover, we can order any new cell line and custom develop your assay as per your specific need.

These are the 29 anti-cancer drugs currently available for research purposes at SBH Sciences:

Adrucil - Fluorouracil (5FU)
Bortezomib (Valcade)
Cyclophosphamide (Cytoxan)
Cisplatin (data), cisplatinum or
cis- Diamminedichloroplatinum (II) (data)
Doxorubicin (data)
Erlotinib (data)
Gefitinib (Iressa)
Gemcitabine Hydrochloride
Imatinib (Gleevec)
Irinotecan HCl
Leptomycin B
Mitomycin C (data)
Neomycin Sulfate
Paclitaxel (Taxol)

SBH Sciences is actively collaborating with Karyopharm Therapeutics in its anti-cancer development program.

We have used over 200 cancer cell lines in this collaboration and we continuing screening for a potential anti-cancer drug. SBH Sciences and Karyopharm Therapeutics have presented ten scientific abstracts together.




Development of Peptide Therapeutics - Bioassay Support

In recent years, there has been a noticeable increase in the number of peptides NCEs entering clinical development as well as an increase in the approved peptide NCEs in the US and rest of the world.The main reason for this increase is related to better production and analytical capabilities that resulted in an increase in the size of peptides being developed as well as increased diversity of molecular targets and therapeutic areas.SBH Sciences' cytokine bioassay capability is the most comprehensive one in the world and includes 330 cell-based assays. We use 370 human cell types (cancer cell lines and primary cells). This vast capability will assist any therapeutic company in their lead drug optimization that is related to therapeutic peptides, either by blocking directly the cytokine or the cytokine-receptor on the cells.We can evaluate the biological activity of peptides after modifications such as cyclization, biotinylation, phosphorylation, glycozylation as well as binding of a specific small MW toxic-drug.Because we provide Luminex and immunological services, we can assess a specific antibody production and therefore we can design, develop and validate the assay to meet your specific requirements.  

Please contact us with your specific needs or any questions related to In-Vitro Oncology investigation and Peptide Therapeutics lead drug development and optimization.